AMD3100 was found to restrain glioblastoma vasculogenesis, specifically blocking the migration of bone marrow-derived cells to the primary tumor site and inhibiting the CXCR4/SDF-1 axis [161]. This evidence concerns the gene CXCL12 and glioblastoma.